Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021 | Zendy

Kun Xu | Zendy; Lianpan Dai | Zendy; George F. Gao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021

Author(s) -

Kun Xu,

Lianpan Dai,

George F. Gao

Publication year - 2021

Publication title -

international immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.86

H-Index - 134

eISSN - 1460-2377

pISSN - 0953-8178

DOI - 10.1093/intimm/dxab061

Subject(s) - reactogenicity , immunogenicity , immunology , clinical trial , covid-19 , immune system , virology , immunity , medicine , coronavirus , biology , disease , infectious disease (medical specialty) , bioinformatics , pathology

Coronavirus disease 2019 (COVID-19) has caused millions of deaths, and serious consequences to public health, economies and societies. Rapid responses in vaccine development have taken place since the isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the release of the viral genome sequence. By 21 May 2021, 101 vaccines were under clinical trials, and published data were available for 18 of them. Clinical study results from some vaccines indicated good immunogenicity and acceptable reactogenicity. Here, we focus on these 18 vaccines that had published clinical data to dissect the induced humoral and cellular immune responses as well as their safety profiles and protection efficacy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research